Markets
Stocks
Mutual Funds & ETF's
Sectors
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Gilead Sciences, Inc.
(NQ:
GILD
)
51.94
USD
+0.91 (+1.78%)
Official Closing Price
/ Updated:
4:00 PM EDT, Jun 18, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
0
Open
50.87
Bid (Size)
51.93 (100)
Ask (Size)
51.94 (37700)
Prev. Close
51.03
Today's Range
50.87 - 52.05
52wk Range
39.20 - 79.37
Shares Outstanding
1,525,355,825
Dividend Yield
N/A
Top News
More News
Secrets to Making Money in PG, MRK, GILD and F
Today 11:00 EDT
from
Marketwired News Releases
Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics
Today 8:00 EDT
Editor Note: For more information about this release, please scroll to bottom.
Read More
from
PR Newswire
More News
Read More
Markets Soar Ahead Of Fed Meeting
June 17, 2013
category
Market News
from
MarketMinute.com Market Updates
CytoDyn Inc. Appoints Anthony D. Caracciolo as Chairman of the Board of Directors
June 17, 2013
from
Business Wire News Releases
Gilead Sciences to Present at the Wells Fargo Securities 2013 Healthcare Conference on Tuesday, June 18
June 17, 2013
from
Business Wire News Releases
Oppenheimer Reiterates Outperform Rating on Gilead Sciences Following Initial Idelalisib Ph.II Results
June 17, 2013
category
Reiteration
,
Oppenheimer
,
Benzinga
, and 4 more.
from
Latest Articles from Benzinga.com
Gilead anuncia los datos provisionales de Fase 2 de idelalisib, que muestran una respuesta en el linfoma no-Hodgkin indolente refractario
June 17, 2013
from
Business Wire Spanish
Gilead Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkin’s Lymphoma
June 17, 2013
from
Business Wire News Releases
Gilead Sciences (GILD) Breaks Through Resistance at $52.47
June 14, 2013
from
Comtex SmarTrend® News Briefs
Trace Insider Trading for Micron, QUALCOMM, Gilead Sciences, Wells Fargo, EMC, and Home Depot
June 14, 2013
from
PR Newswire
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here